Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review
Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/12/1644 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085317352095744 |
|---|---|
| author | João Luís Q. Simei José Diogo R. Souza João Francisco Pedrazzi Francisco S. Guimarães Alline Cristina Campos Antônio Zuardi Jaime Eduardo C. Hallak José Alexandre S. Crippa |
| author_facet | João Luís Q. Simei José Diogo R. Souza João Francisco Pedrazzi Francisco S. Guimarães Alline Cristina Campos Antônio Zuardi Jaime Eduardo C. Hallak José Alexandre S. Crippa |
| author_sort | João Luís Q. Simei |
| collection | DOAJ |
| description | Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness. Outcomes: A narrative review was conducted to discuss the best evidence regarding the pharmacological profile of CBD, its efficacy, and safety within the context of regulation and perspectives on the development of new cannabinoid-based drugs. Key articles addressing the various facets of this issue were selected for comprehensive analysis. Conclusions: Clinicians and researchers may face unique challenges in understanding the pharmacological profile of CBD and the prospects for developing its clinical indications, given the heterogeneity of clinical terminologies and the quality and composition of cannabis-based medical products available on the market. More basic and clinical research that complies with regulatory agencies’ testing guidelines, such as good manufacturing practices (GMPs), good laboratory practices (GLPs), and good clinical practices (GCPs), is needed to obtain approval for CBD or any other cannabinoid as a therapeutic for broader clinical indications. |
| format | Article |
| id | doaj-art-4cec5e0ec4714cd98c393a4298bffdde |
| institution | DOAJ |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-4cec5e0ec4714cd98c393a4298bffdde2025-08-20T02:43:45ZengMDPI AGPharmaceuticals1424-82472024-12-011712164410.3390/ph17121644Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative ReviewJoão Luís Q. Simei0José Diogo R. Souza1João Francisco Pedrazzi2Francisco S. Guimarães3Alline Cristina Campos4Antônio Zuardi5Jaime Eduardo C. Hallak6José Alexandre S. Crippa7Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilNational Institute for Science and Technology-Translational Medicine, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, BrazilBackground: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness. Outcomes: A narrative review was conducted to discuss the best evidence regarding the pharmacological profile of CBD, its efficacy, and safety within the context of regulation and perspectives on the development of new cannabinoid-based drugs. Key articles addressing the various facets of this issue were selected for comprehensive analysis. Conclusions: Clinicians and researchers may face unique challenges in understanding the pharmacological profile of CBD and the prospects for developing its clinical indications, given the heterogeneity of clinical terminologies and the quality and composition of cannabis-based medical products available on the market. More basic and clinical research that complies with regulatory agencies’ testing guidelines, such as good manufacturing practices (GMPs), good laboratory practices (GLPs), and good clinical practices (GCPs), is needed to obtain approval for CBD or any other cannabinoid as a therapeutic for broader clinical indications.https://www.mdpi.com/1424-8247/17/12/1644cannabisphytocannabinoidscannabidiolendocannabinoid systempharmacologydrug development |
| spellingShingle | João Luís Q. Simei José Diogo R. Souza João Francisco Pedrazzi Francisco S. Guimarães Alline Cristina Campos Antônio Zuardi Jaime Eduardo C. Hallak José Alexandre S. Crippa Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review Pharmaceuticals cannabis phytocannabinoids cannabidiol endocannabinoid system pharmacology drug development |
| title | Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review |
| title_full | Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review |
| title_fullStr | Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review |
| title_full_unstemmed | Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review |
| title_short | Research and Clinical Practice Involving the Use of <i>Cannabis</i> Products, with Emphasis on Cannabidiol: A Narrative Review |
| title_sort | research and clinical practice involving the use of i cannabis i products with emphasis on cannabidiol a narrative review |
| topic | cannabis phytocannabinoids cannabidiol endocannabinoid system pharmacology drug development |
| url | https://www.mdpi.com/1424-8247/17/12/1644 |
| work_keys_str_mv | AT joaoluisqsimei researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT josediogorsouza researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT joaofranciscopedrazzi researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT franciscosguimaraes researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT allinecristinacampos researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT antoniozuardi researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT jaimeeduardochallak researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview AT josealexandrescrippa researchandclinicalpracticeinvolvingtheuseoficannabisiproductswithemphasisoncannabidiolanarrativereview |